PL1906916T3 - Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku - Google Patents

Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku

Info

Publication number
PL1906916T3
PL1906916T3 PL06759259T PL06759259T PL1906916T3 PL 1906916 T3 PL1906916 T3 PL 1906916T3 PL 06759259 T PL06759259 T PL 06759259T PL 06759259 T PL06759259 T PL 06759259T PL 1906916 T3 PL1906916 T3 PL 1906916T3
Authority
PL
Poland
Prior art keywords
ophthalmic
poloxamine
adjusting agent
medicament
manufacture
Prior art date
Application number
PL06759259T
Other languages
English (en)
Inventor
Geoffrey Robert Owen
Amy C Brooks
Gustav Graff
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of PL1906916T3 publication Critical patent/PL1906916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06759259T 2005-05-10 2006-05-08 Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku PL1906916T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67951005P 2005-05-10 2005-05-10
PCT/US2006/017607 WO2006121964A2 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
EP06759259A EP1906916B1 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Publications (1)

Publication Number Publication Date
PL1906916T3 true PL1906916T3 (pl) 2009-02-27

Family

ID=37087751

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06759259T PL1906916T3 (pl) 2005-05-10 2006-05-08 Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku

Country Status (19)

Country Link
US (1) US20060257486A1 (pl)
EP (1) EP1906916B1 (pl)
JP (1) JP4968955B2 (pl)
KR (1) KR20080011311A (pl)
CN (1) CN101175476B (pl)
AT (1) ATE412402T1 (pl)
AU (1) AU2006244245B2 (pl)
BR (1) BRPI0608774A2 (pl)
CA (1) CA2607014A1 (pl)
CY (1) CY1108676T1 (pl)
DE (1) DE602006003438D1 (pl)
DK (1) DK1906916T3 (pl)
ES (1) ES2313670T3 (pl)
MX (1) MX2007014084A (pl)
PL (1) PL1906916T3 (pl)
PT (1) PT1906916E (pl)
SI (1) SI1906916T1 (pl)
WO (1) WO2006121964A2 (pl)
ZA (1) ZA200709296B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101175475B (zh) * 2005-05-10 2010-04-14 爱尔康公司 包含活性成分、泊洛沙姆或美洛沙泊表面活性剂和二醇的混悬制剂、其用于生产治疗眼科病症的药物的用途
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2403342A4 (en) * 2009-03-03 2013-06-05 Alcon Res Ltd PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
PT2965749T (pt) * 2009-12-03 2018-10-09 Novartis Ag Supensões de nanopartículas contendo um polímero de carboxivinilo
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP2609933A4 (en) * 2010-08-27 2014-04-09 Wakamoto Pharma Co Ltd AQUEOUS COMPOSITION FOR ADMINISTRATION
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN111285845B (zh) * 2020-02-11 2021-01-01 深圳厚存纳米药业有限公司 末端官能团化的泊洛沙胺衍生物
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
JP2024506384A (ja) * 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
US20240108609A1 (en) * 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
CN1204240C (zh) * 1997-07-29 2005-06-01 阿尔康实验室公司 硬性隐形眼镜护理调节液
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20020115578A1 (en) * 2000-12-14 2002-08-22 Groemminger Suzanne F. Composition for cleaning and wetting contact lenses
WO2002078681A2 (en) * 2001-04-02 2002-10-10 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
JP2003137775A (ja) * 2001-10-31 2003-05-14 Menicon Co Ltd 眼科用組成物
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US20040029771A1 (en) * 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
JPWO2004084877A1 (ja) * 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
CN101175475B (zh) * 2005-05-10 2010-04-14 爱尔康公司 包含活性成分、泊洛沙姆或美洛沙泊表面活性剂和二醇的混悬制剂、其用于生产治疗眼科病症的药物的用途

Also Published As

Publication number Publication date
EP1906916A2 (en) 2008-04-09
JP2008540533A (ja) 2008-11-20
CA2607014A1 (en) 2006-11-16
EP1906916B1 (en) 2008-10-29
ES2313670T3 (es) 2009-03-01
BRPI0608774A2 (pt) 2010-01-26
ATE412402T1 (de) 2008-11-15
AU2006244245A1 (en) 2006-11-16
CN101175476B (zh) 2011-11-16
AU2006244245B2 (en) 2010-11-18
ZA200709296B (en) 2009-01-28
PT1906916E (pt) 2008-12-10
KR20080011311A (ko) 2008-02-01
WO2006121964A3 (en) 2007-03-22
WO2006121964A2 (en) 2006-11-16
JP4968955B2 (ja) 2012-07-04
US20060257486A1 (en) 2006-11-16
CN101175476A (zh) 2008-05-07
DK1906916T3 (da) 2009-01-19
MX2007014084A (es) 2008-02-07
SI1906916T1 (sl) 2009-02-28
DE602006003438D1 (de) 2008-12-11
CY1108676T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
MY145074A (en) Thiazolidin-4-one derivatives
TW200626132A (en) Topical nepafenac formulations
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo
SE0101932D0 (sv) Pharmaceutical combinations
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
TW200730190A (en) New combination to treat liver fibrosis
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2008004100A3 (en) Therapeutic compounds
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2007121471A3 (en) Dialkyl ether delivery agents
WO2007022532A3 (en) Cyclopropyl compounds and compositions for delivering active agents
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
WO2008144690A3 (en) Compositions and methods for enhancing active agent absorption
MY142039A (en) New association between a heterocyclic compound and an antioxidant agent, and pharmaceutical compositions containing them